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A homeopathic complex medication (HCM), with immunomodulatory properties, is recommended for patients with depressed
immune systems. Previous studies demonstrated that the medication induces an increase in leukocyte number. The bone marrow
microenvironment is composed of growth factors, stromal cells, an extracellular matrix and progenitor cells that diﬀerentiate into
mature blood cells. Mice were our biological model used in this research. We now report in vivo immunophenotyping of total
bone marrow cells and ex vivo eﬀects of the medication on mononuclear cell diﬀerentiation at diﬀerent times. Cells were examined
by light microscopy and cytokine levels were measured in vitro.A f t e rin vivo treatment with HCM, a pool of cells from the new
marrow microenvironment was analyzed by ﬂow cytometry to detect any trend in cell alteration. The results showed decreases,
mainly, in CD11b and TER-119 markers compared with controls. Mononuclear cells were used to analyze the eﬀects of ex vivo
HCM treatment and the number of cells showing ring nuclei, niche cells and activated macrophages increased in culture, even in
the absence of macrophage colony-stimulating factor. Cytokines favoring stromal cell survival and diﬀerentiation in culture were
induced in vitro. Thus, we observe that HCM is immunomodulatory, either alone or in association with other products.
1.Introduction
Recently, great advances in conventional medicine have
included the discovery of powerful new drugs the requested
bibliographies such as 2-chloro-2-deoxyadenosine (CdA) for
use in patients with various types of cytopenia and oppor-
tunistic infections [1], and Decitabine, a cytosine analog
used at lower doses for the treatment of myelodysplastic
syndrome [2]. In addition, biomarker and drug studies have
aided in the development of personalized medicines [3].
Such new medications act to assist rapid patient recovery,
but with side eﬀects, which reduce quality-of-life. In this
context, Conforti and collaborators in 2007 [4], comment
the action of conventional anti-inﬂammatory drugs and
compare with, homeopathic treatment who is used to
regulate the pathological excess of inﬂammation expressing
thenaturalhealingdynamicsandtheeﬃcacyofhighdilution
of active natural substances. Previous studies demonstrated
that a homeopathic complex medication (HCM) activates
macrophages (MΦ)b o t hin vivo and in vitro.I tw a so b s e rv e d
that the in vitro production of tumor necrosis factor-α
(TNF-α)b yM Φ was signiﬁcantly reduced when HCM
was administered [5]. NADPH oxidase activity increased
after HCM ingestion, as did that of inducible nitric oxide
synthetase(iNOS),resultinginproductionofreactiveoxygen
species (ROS) and nitric oxide (NO), respectively [6].
HCM stimulated the endosomal/lysosomal system and the
phagocytic activity of MΦ interacting with Saccharomyces
cerevisiae and Trypanosoma cruzi epimastigotes [7]. The
modulatory eﬀects of HCM were also observed both in vivo
andinvitroinexperimentalinfectionswithLeishmaniaama-
zonensis and Paracoccidioides braziliensis; HCM controlled
infection progression and limited pathogen dissemination
[8, 9]. Moreover, HCM is neither toxic nor mutagenic [10].
Similarly, improvement in the immune response of mice
bearing Sarcoma-180 tumors was seen after HCM treatment.
In the cited study, a reduction in sarcoma size was shown
and lymphoid cells signiﬁcantly inﬁltrated the tumors;
granulation tissue and ﬁbrosis surrounded the sarcomas. All
animals of the treated group survived, and, in 30% of mice,2 Evidence-Based Complementary and Alternative Medicine
complete tumor regression was observed. The total number
of leukocytes was increased by HCM treatment. Among
lymphocyte classes, T-CD4, B and natural killer (NK) cells
increased in number [11]. These results suggested that HCM
aﬀected hematopoiesis either directly or indirectly. Bone
marrow cells were treated with HCM in vitro and examined
by light, scanning electron, and confocal microscopy. These
modalities, and also ﬂow cytometry, indicated that cells of
the monocytic lineage (CD11b) and stromal cells (adherent
cells)wereactivatedbyHCMtreatment,whichalsoincreased
cell clusters over adherent cells, suggesting that cell prolifer-
ation and diﬀerentiation were taking place [12, 13].
The microenvironment inﬂuences growth and diﬀerenti-
ation of hematopoietic cells. Adherent cell layers elaborate
soluble factors and deposit extracellular matrix which, in
turn, inﬂuence hematopoietic proliferation and diﬀeren-
tiation [14, 15]. The diﬀerentiation of monocytic cells
into monoblasts, promonocytes, and monocytes (Mo), is
stimulated by macrophage colony-stimulating factor (M-
CSF) [16]. This factor acts principally to stimulate the prolif-
eration of progenitors committed to MΦ lineages [17–20].
Mo, tissue MΦ, dendritic cells (DCs), microglia and
osteoclasts all contribute to maintenance of tissue home-
ostasis and provide a ﬁrst line of defense against invading
pathogens. These cell types are produced in bone marrow,
and undergo diﬀerentiation therein before being released to
peripheral blood. The recovery of myelopoiesis to normal
levels would contribute signiﬁcantly to increased life-span
by preventing delayed severe side eﬀects (e.g., secondary
infections) after chemotherapy. Provision to the periphery of
more Mo/MΦ, and normalization of bone marrow cellular-
ity, might also permit more intensive patient treatment.
Thus, the aim of this study was to use in vitro, in vivo
and ex vivo techniques to examine whether HCM stimulates
a preferential response of the Mo/MΦ lineage in the place of
origin, the microenvironment surrounding progenitor cells.
2. Methods
2.1. Animals. Male Swiss mice of the Rockefeller lineage
(10–12 weeks of age) were kindly supplied by the Instituto
de Tecnologia do Paran´ a (TECPAR). Animals had free
access to food and water. All recommendations of the
National Law (No. 6.638; 5 November 1979) for scientiﬁc
animal management were observed and the Institutional
Animal Care Committee of the Universidade Federal do
Paran´ a approved all relevant practices. Experiments were
carried out at the Laboratory of Research in Neoplastic and
Inﬂammatory Cells, which has a management program for
animal residues.
2.2. Animal Treatment. The following groups were estab-
lished:
Group 1: control group; mice did not receive any
treatment;
Group 2: mice treated with HCM
Group 3: mice treated with both HCM and M-CSF;
Group 4: positive control; mice treated with M-CSF.
Mice were subcutaneously treated at daily intervals for 7
days. Animals receiving HCM were given doses of 7μLg −1
body weight per day. Mice of group 3 received 2.8μLg −1
of HCM and 4.2μLg −1 of M-CSF per day. These amounts
were calculated to reﬂect concentrations used in in vitro
experiments [9]. After 7 days of treatment animals were
euthanized by cervical dislocation and bone marrow cells
were obtained as described below. Cells were processed
following routine protocols. Experiments were performed at
least three times in quadruplicate, independently. A total of
100 animals were used.
2.3. Bone Marrow Preparation (In Vitro and In Vivo). After
cervical dislocation femurs were dissected and cleaned.
Epiphyses were removed and the marrow was ﬂushed with
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) contain-
ing 10% (v/v) fetal bovine serum (FBS) and 1μgmL −1
ciproﬂoxacin (all from Sigma Pharma, St. Louis, MO). Some
cells were used for immunophenotyping and the remaining
cells were puriﬁed on 1.077 Ficoll-Hypaque (FH) (Sigma).
This product is a solution of Ficoll and sodium diatrizoate
adjusted to a density of 1.077gmL−1. When blood is
overlaid and the solution is centrifuged, mononuclear cells
concentrate at the plasma-reagent interface [21]. For FH
puriﬁcation, 10mL of ﬂushed bone marrow aspirate was
layeredonto3mLofFHsolutioninasterile15mLcentrifuge
tube. The tube was capped and centrifuged in a tabletop
centrifuge at 1500g for 40min at room temperature. A
diﬀusebandofleukocytes(mononuclearcells)formedabove
the erythrocytes and polymorphonuclear cells, which were
together in the pellet. This diﬀuse cell layer was aseptically
removed with a pipette and transferred to a sterile 15mL
centrifuge tube. Cells were washed with phosphate buﬀered
saline (PBS) because Ficoll is toxic to cells. Mononuclear
cells were counted in a Neubauer chamber and suspended in
DMEM with 10% (v/v) FBS supplemented with 1μgmL −1
ciproﬂoxacin and 4 mM l-glutamine (Sigma).
2.4. The HCM. HCM is a new immunomodulatory therapy
and formulation follows Hahnemann’s ancient homeopathic
techniques. HCM is an aqueous, colorless and odorless solu-
t i o np r o d u c e da n ds o l di na u t h o r i z e dd r u g s t o r e si nB r a z i l .
Mother tinctures are purchased from agencies authorized
by the Brazilian Health Ministry. These agencies assure the
quality (endotoxin-free) and physicochemical composition
of the product. Starting from the original mother tincture
(e.g., a plant ethanolic extract), several dynamizations
(succussion, or shaking, and dilution in distilled water) are
performed. Decimal dilutions (dH) are prepared. The ﬁnal
commercialproductiscomposedof11dHAconitumnapellus
(Ranunculaceae), 19dH Thuya occidentalis (Cupressaceae),
18dH Bryonia alba (Curcubitaceae),19dH Arsenicum album
(arsenic trioxide), 18dH Lachesis muta (Viperidae), and
<1% (v/v) ethanol, in distilled water. We used the com-
mercial product of Narciso da Lozzo Neto, batch number
CRF-PR 5604. A homeopathy principle is that substance
eﬀects become stronger with dilution and dynamization.
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potency. The medication was always vigorously succussed
immediately before use.
2.5. Preparation of L929-Conditioned Medium. M-CSF is
highly expressed by the L929 mouse cell line [22] and L929
cell-conditioned medium was used as a source of M-CSF for
cellsculturedinplasticdishesinDMEMwith10%(v/v)FBS;
L-cell conditioned medium was added to 30% (v/v). As M-
CSF was not a mother tincture, a high dilution (as used for
HCM) was not employed, nor was succussion necessary.
ToobtainL929cell-conditionedmedium,L929cellswere
seeded in culture bottles (150cm2) to a density of 1 × 106
cells per bottle, and cultivated in DMEM, which is rich in
glucose, supplemented with 5% (v/v) FBS. The conditioned
medium was collected after 7 days, at which time the cells
were conﬂuent. The medium was centrifuged to remove cells
and the supernatant was stored at −20◦C until use. M-CSF
was stable under these conditions for more than 6 months.
Oncethawed,aliquotswerestoredat0◦CtoavoidtheM-CSF
degradation that occurs during freeze-thaw cycles.
2.6. Liquid Culture (In Vitro). Cells were adjusted to a
concentration of 2.5 × 105/mL, plated in 24-well culture
plates, and maintained at 37◦C under a 95% air/5% CO2
atmospherefor96h.Allexperimentswereperformedatleast
three times in quadruplicate; there were four animal groups.
Controls received no treatment, because our previous results
showednostatisticaldiﬀerencesbetweenacontrolgroupand
an ethanolic aqueous solution group. Cells of group 2 were
treated with 20% (v/v) HCM. The M-CSF groups received
30% (v/v) M-CSF medium and, in group 3, cellswere treated
with both M-CSF medium and 20% (v/v) HCM. Groups
2 and 3 also received 1% (v/v) HCM daily, at precise 24h
intervals.
2.7. Cytokine Quantiﬁcation (In Vitro). After 96h of cul-
ture adherent cells had increased in number. Supernatant
cytokine levels were measured using a mouse Th1/Th2
cytokine CBA kit (BD Pharmingen, USA), according to
the manufacturer’s instructions. The kit contains antibodies
against TNF-α, interferon-γ (IFN-γ), and interleukins 2,
4 and 5 (IL-2, IL-4, IL-5). Cytokine concentrations were
obtained by comparison of experimental data with standard
curves of the CBA program (Becton Dickinson). Fluores-
cence was measured using a FACSCalibur ﬂow cytometer
(Becton Dickinson), equipped with an argon ion laser
(488nm).
2.8. Immunophenotyping. This experiment was preliminary
in nature, and was performed to guide further work. After in
vivo treatment immunophenotyping was performed as soon
as cells were collected. Cells (106) were ﬁxed with 1% (v/v)
paraformaldehyde, washed, and incubated with 0.5μgmL −1
ofthebiotinylated antibodies listedbelow,inPBSfor40min.
Cells were washed with PBS and incubated with 0.5μgmL −1
phycoerythrin (PE)-labeled secondary antibody in PBS for
30 minutes [23]. Fluorescence was analyzed according to
Table 1
Antibody Principal cell types marked
CD11b (Mac-1) Monocytes/macrophages
Ly-6G Granulocytes
CD45R B-lymphocytes
CD11c Dendritic cells
CD3 T-lymphocytes
TER-119 Erythrocytes
standard procedures using a FACSCalibur ﬂow cytometer.
Data were analyzed by Cell Quest.
2.9. Surface Markers. All antibodies used were from a mouse
lineage panel, speciﬁc to bone marrow, and were purchased
from BD Pharmingen (see Table 1).
2.10. Ex Vivo Culture Conditions. Animals were treated as
described above and bone marrow cells were collected.
Mononuclear cells were puriﬁed, concentrated to 2.5 ×
105 cells/mL, plated in 24-well culture plates with glass
coverslips for adherent cell experiments, and maintained at
37◦C under 95% air/5% CO2 for 24, 48, and 72h. Groups 2
and 3 received 1% (w/v) HCM daily, precisely 24h after the
preceding dose.
2.11. Morphological Assay. Cells (2.5 × 105) were plated into
culture plates with coverslips for morphological analysis [24]
and maintained as described above. After 24, 48 and 72h,
cells were rinsed with PBS, ﬁxed in Bouin, stained with
Giemsa, dehydrated and mounted with Entellan. Adherent
cellswereobservedbylightmicroscopyusingaNikonEclipse
E200. Structural characteristics of lymphocytes, resident
macrophages, activated macrophages, cell niches and cells
with ring-shaped nuclei, were sought. On each cover slip,
100 cells were examined. Ten cover slips for each treatment
and timepoint were prepared and analyzed. Mean data, in
percentages, were transformed as described below.
2.12. Statistical Analysis. In cytokines experiments, data
were analyzed with Cell Quest software, according to the
manufacturer’s instructions. ANOVA and the Tukey test
(signiﬁcance:P <.05)wereusedforintergroupcomparisons.
Percentagedata,obtainedfromlightmicroscopyanalysis,
weretransformedto
√
x +0 .5values,togivenormaldistribu-
tions. Data were submitted to analysis of variance (ANOVA)
with a factorial diagram, randomly delineated, to determine
statistical signiﬁcance. The Tukey test was performed when
aninteractioneﬀectwassigniﬁcant.Thelevelsofsigniﬁcance
were taken to be ∗P < .05 and ∗∗P < .01.
3. Results
3.1. Cytokine Quantiﬁcation (In Vitro). After 96 h of culture,
we evaluated the capacities of cells to produce TNF-α,I F N - γ,
IL-2,IL-4and IL-5.TNF-α wassigniﬁcantly higher ingroups
2a n d3t h a ni ng r o u p s1a n d4( Figure 1).4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Cytokine quantiﬁcation in vitro. Mice were euthanized
and mononuclear cells were obtained by Ficoll separation. Cells
were cultured and in vitro treated. After 96h, supernatants were
collectedandcytokinelevelsanalyzed.Theseresultsarepresentedas
mean ± SEM. The signiﬁcance of diﬀerences between mean values
was evaluated by two-way analysis of variance (ANOVA) followed
by Tukey test. ∗P <.05wereconsideredstatisticallysigniﬁcant.Only
the TNF-α data are statistically signiﬁcant at ∗P < .05. Data are
representative of three independent experiments.
3.2. Immunophenotyping. After in vivo treatment, bone mar-
row cells were analyzed by ﬂow cytometry. Cell populations
were similar to those seen by Civin and Loken in 1987
[25]. The mean percentage of each population is shown in
Figure 2. We observed that in vivo treatment with HCM
decreased the number of CD11b cells (in the Mo lineage).
Group 4 (M-CSF treatment) showed more CD11b cells than
did group 1 (control); this was expected, as M-CSF is a
growth factor speciﬁc for this lineage. When HCM was given
together with M-CSF (group 3), the data were similar to
those of group 2 treated only with HCM.
Dendritic cells (CD11c+) were reduced by HCM treat-
ment compared to the control group (group 1). The other
groups (3 and 4) showed the same tendency. Granulocytes
(Ly6G+) and T-lymphocytes (CD3+) were apparently down-
regulated by HCM treatment, but the reduction was very
subtle. When HCM was administered together with M-CSF,
the reduction was not observed. B-lymphocytes (CD45R+)
were diminished by HCM treatment in group 2, although
groups 3 and 4 also showed slight reductions. Erythrocytes
(TER-119+) were reduced only in the group treated with
HCM alone (group 2).
3.3. Morphological Assay. Mononuclear cells obtained from
bone marrow of in vivo treated animals were observed
by light microscopy and characterized by cell morphology.
Each cell type was counted, and the data obtained were
analyzed statistically. Analysis was performed for each cell
type, treatment, and culture time. Adherent cells were
characterized as follows.
Immunophenotyping in vivo total markers used
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Figure 2: Immunophenotyping. An aliquot was used to analyze the
cells just after collecting. Mice were euthanized and bone marrow
cells were removed. Aliquots of freshly collected cells were analyzed
by ﬂow cytometry. Group 1: control group; Group 2: mice treated
with HCM; Group 3: mice treated with HCM and MCSF; Group
4: mice treated with M-CSF. We show data on all markers used
in analysis. All bone marrow cells after in vivo treatment were
s u b j e c t e dt oﬂ o wc y t o m e t r yt od e t e c ta n yt r e n di nc e l la l t e r a t i o n .
DecreasesinCD11bandTER-119markersintestgroups,compared
to controls, may be noted.
3.3.1.Lymphocytes. Lymphocyteswerecharacterizedbytheir
classical morphology, showing rounded small nuclei with
condensed chromatin and a thin cytoplasm (Figures 3(a)
and 4(a)). After lymphocyte statistical analysis we showed
diﬀerences only when treatment and culture times were
separately compared. Lymphocyte numbers decreased over
48h and the lower numbers were maintained to 72h
(Figure 4). Group 3 tended to show fewer lymphocytes than
did other groups.
3.3.2. Resident MΦ. Resident MΦ were characterized by
classical ﬁbroblast-like morphology with a central nucleus,
little cytoplasm with few extensions, resulting in an elon-
gated (so not a spread) appearance. Such cells had small,
condensed and “kidney”-shaped nuclei (Figures 3(b) and
4(b)). As for lymphocytes, resident MΦ data analysis showed
diﬀerences only when treatment and culture times were
separately compared. We found that group 1 (control) had
more resident MΦ (mostly round, with fewer membrane
extensions); such cells were rarer in groups 2, 3 and
4. This corroborates previous work showing that HCM
activates MΦ, thus decreasing the number of resident MΦ.
Although growth factors were absent, we found that after
72hfewerresidentMΦremainedadherenttoglasscoverslips
(Figure 4).
3.3.3. Activated MΦ. The morphological characteristics of
activated MΦ are increased membrane ruﬄing, increased
spreading and large and euchromatic nuclei (Figures 3(a),
3(b),a n d4(c)). When we examined both treatment and
culture time, we observed that the numbers of activated MΦ
increasedwithtimeinallgroups,buttherewasnosigniﬁcant
diﬀerence between treatment groups. The addition of HCM,Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Microphotography of mononuclear bone marrow cells. Animals were treated in vivo and bone marrow cells were collected.
Mononuclear cells were separated, concentrated to 2.5 × 105cells/mL, plated on 24-well culture plates with glass coverslips as for the
adherent cell experiments, and maintained at 37◦C under 95% air/5% CO2 for 24, 48 and 72h. Cells were stained with Giemsa. Original
magniﬁcation:40×.In(c)and(d),weshowringcellsandin(e)and(f),weemphasizenichesfoundingroups2and3after48h,respectively.
In (a) it is possible to compare lymphocytes (Ly) and activated macrophages (Am) in the positive control (group 4) and in (b) (group 1; the
negative control), resident macrophages (Rm) and active macrophages (Am) are seen (Bar = 10Gm).
M-CSF, or both, to cultures, increased cell spreading and cell
density.
3.3.4. Cells with Ring-Shaped Nuclei. We found cells with
constrictedring-shapednucleiandwidecytoplasmiccenters.
Weobservedtwosuchtypesofcells:polymorphonuclear-like
ring cells (PMN-LR) with lobular or constricted ring-shaped
nuclei and a cytoplasmic center larger than the width of
the ring (Figures 3(d) and 5(a)), and mononuclear-like ring
cells (MNC-LR) with ring-shaped nuclei of smooth contour
and cytoplasmic centers smaller than the width of the ring
(Figures 3(c), 3(d),a n d5(b)). With this cell type, ANOVA
showed that all interactions were signiﬁcant and the Tukey
test was performed. In groups 2 and 3 these cells appeared at
24h and increased in number over the next 24h. After 72h
the numbers of such cells decreased in all groups these dates
are showed in Figure 5.
3.3.5. Cell Niches. Cell niches were associated with adherent
layers in small foci over stromal cells (Figures 3(e), 3(f),a n d
6(a)). After ANOVA analysis we found that all interactions
were signiﬁcant and the Tukey test was performed to6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Lymphocytes (Ly), resident macrophages (Rm), and activated macrophages (Ac). Adherent cells were counted at three culture
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Figure 5: Cells with ring-shaped nuclei (Ring-shaped nuclei cells
was removed). These adherent cells were counted. The ex vivo
treatment showed maintenance of this cell type upon culture and
the levels of such cells increased in 48h of culture. The numbers
are perceptual means; ∗P < .05 and ∗∗P < .01. These results are
presented as mean ± SEM.
compare the means. Groups 2 and 3 showed a higher level
of cell niches at 24h and 48h, but this decreased with culture
time. These dates are showed in Figure 6.
For better representation of our results, we constructed a
schematic representation (Figure 7) to show the eﬀect of the
medicament in all aspects analyzed.
4. Discussion
Hematopoietic cells proliferate in vivo and develop in
association with bone marrow stromal cells. Proliferation
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Figure 6: Cellular niches. Cells in niches were counted among
adherent cells. We emphasize that this type of cell arrangement was
seen immediately upon plating after in vivo treatment. The niches
were maintained for 48h, decreasing in number after 72h. The
numbersareperceptualmeans; ∗P <.05.Theseresultsarepresented
as mean ± SEM.
and diﬀerentiation also occur in vitro, either in association
with stromal cells or in response to soluble growth factors.
Our in vitro studies have shown that HCM promotes growth
and diﬀerentiation of myelomonocytic cells in normal mice
[12, 13]. Stromal cells produce diﬀerent types of growth
factors leading to the formation of microenvironments that
allow cell diﬀerentiation into speciﬁc lineages.
Homeopathic regulation can be obtained through the
similia principle in health body of what constitutes the
vital force and its possible dynamic alterations and couldEvidence-Based Complementary and Alternative Medicine 7
Bone marrow after HCM treatment
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cell migration
to peripheral
blood
Cell niches and ring-
shaped nuclei cells
decreased after 72
hours
TNF-α
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Figure 7: After 96h of in vitro treatment the TNF-α concentration has shown a signiﬁcant increase. After in vivo treatment, it was decreased
the number of monocyte/macrophages cells (CD11b+), dendritic cells (CD11c+), granulocytes (Ly6G+), B lymphocytes (CD45R+), T
lymphocytes (CD3+) and speciﬁcally in group 2, erythrocytes (TER-119+). Cell niches and cells with ring-shaped nuclei were present in
the ﬁrst 48h, and after this diminished.
be translated in today’s terms as both homeodynamic and
communication disorders. Bellavite and collaborators [26]
mentioned that, when a factor of imbalance occurs a signal
is triggered and the system increases its activity producing a
greater amount of signal (e.g., IL-1, cytokines, interferons),
released from inﬂammatory exudate, thus bringing the
eﬀector system (phagocytes or complement) back to its
normal homeodynamic, by eliminating a signal excess and
re-establishing condition (healing).
First, several proinﬂammatory cytokines and chemo-
kines are simultaneously induced by viral and bacterial
products in infected or inﬂamed tissue, and cytokines
can co-operate even within a single cell type [27]. Subse-
quently,host-derived cytokines actsynergistically to enhance
chemokineinduction[28].Alternatively,someinﬂammatory
chemokines may cooperate with constitutively produced
chemokines to inﬂuence the distribution of both immature
and mature hematopoietic cells, including cell release into
the circulation or homing to the bone marrow. Our results
showed an increase in TNF-α production when HCM
was added to cultures. TNF-α is an important cytokine
with hematopoietic-regulating activities, targeting speciﬁc
population(s) of bone marrow cells. TNF-α has pleiotropic
eﬀects on hematopoiesis, depending on the target cells
involved,thedevelopmentalstageoftargetcells,orboth[29].
Leukocyte production in the bone marrow is controlled
byinﬂammatorycytokines.Actinginconcert,TNF-αandIL-
1 induce the loss of bone marrow lymphocytes by emigra-
tion while signiﬁcantly expanding granulocyte production.
Zhang and collaborators, in 1995 [30], established that TNF-
α is a bifunctional regulator of hematopoiesis. A single dose
of the cytokine stimulated the growth of immature murine
myeloid progenitors, whereas daily injections induced a
slight decrease in such progenitors, accompanied by neu-
trophilia and lymphopenia. The eﬀects of TNF-α on the
growth of hematopoietic stem and progenitor cells may
change, depending on the phase of the cell cycle. This
cytokinecansuppressthegrowthofearlyhematopoieticpro-
genitor cells in vivo and in vitro. We found elevated numbers
of cells with ring nuclei in groups 2 and 3, suggesting that
HCM stimulates the movement of granulocyte precursors, as
well as Mo, from bone marrow to the circulation.
Cells with ring nuclei were described as Mo/MΦ lineage
precursors by Biermann and colleagues in 1999 [31], not
only in rodents, but also in hamsters and humans. Patients
with mononucleosis and myeloproliferative disorders also
present with these cell types. Diﬀerent types of cells with
ring nuclei were found within 24h of HCM treatment,
including polymorphonuclear-like ring cells (PMN-LR) and
mononuclear-like ring cells (MNC-LR). The number of8 Evidence-Based Complementary and Alternative Medicine
cells with ring nuclei increased signiﬁcantly after 48h of
treatment, but diminished with time thereafter (Figure 5).
Similarly, it is important to note that immunophenotyping
showed that the speciﬁc granulocytic lineage marker (Ly6G)
increased in group 3 (Figure 2). Adhesion, during at least
one period of culture, is a feature diﬀerentiating Mo/MΦ
and PMN cells from other leukocytes. As ring nuclei cells
are of myeloid origin and are Mo/MΦ and PMN precursors,
we suggest that, after adhesion for a period between 24 and
48h, diﬀerentiated PMN detach to the supernatant. The
MΦ precursors remain adherent, increasing the number of
activated MΦ in cultures treated for 72h (Figure 4).
In ours morphological results, we observed cell clusters
over the adherent cells (Figure 6), suggesting sites of multi-
plication and diﬀerentiation called cell niches. These niches
are known to contain stem cells [32] and/or leukocytes com-
mitted with some cellular lineage [33, 34]. The adherent cell
clusters are dependent on direct cell-to-cell communication,
as well as cytokines and growth factors (colony forming)
[35]. In bone marrow erythropoiesis, erythroid cells are
organized in small anatomic units termed erythroblastic
islets, the islet cells diﬀerentiate into cells of the erythroid
series, and with MΦ, create these peculiar anatomic units.
Soni and co-workers, in 2007 [36], showed that the ery-
throblast macrophage protein (EMP) is responsible for
erythroblast linkage to MΦ on the erythroblastic islets. Each
islet is composed of one MΦ surrounded by erythroblasts
at diﬀerent stages of maturation. Mature erythroblasts are
considered to move along the cytoplasmic extension of a
central MΦ toward the sinusoid [37].
Belon and collaborators, in 2007 [38], mentioned the
Arsenicum album administered in homeopathic doses
(Arsenicum album-30 and Arsenicum album-200) to
revert the alarmingly high incidence of elevated ANA
titers observed in random populations of high-risk arsenic
contaminated villages in West Bengal, India. Positive mod-
ulation was observed along with changes in certain relevant
hematological parameters, namely total count of red blood
cells and white blood cells, packed cell volume, hemoglobin
content, erythrocyte sedimentation rate and blood sugar
level, mostly within 2 months of drug administration. A
complex homeopathic medicine is produced from Aconitum
napellus, Thuya occidentalis, Bryonia alba, Lachesis muta
and Arsenicum album. It seems to enhance the individual’s
own immunity to trigger a particular immunologic response
against several pathological conditions [5–9, 11].
Even the Immunophenotyping results, were our prelim-
inary experiment, it was demonstrated that HCM treatment
decreased expression of the TER-119 marker speciﬁc to the
erythrocytic lineage (Figure 2). There are two possible expla-
nations for this reduction. Either the maturation process was
accelerated by HCM treatment (thus allowing cell migration
to the peripheral circulation) or immature cells adhered in
niches formed over stromal cells, thus evading detection
by ﬂow cytometry. Chen and collaborators [39], genomic
approach(microarrayanalysis)foundup-regulatedgenesare
thegenescodingforhemehoxygenaseHMOX-1inresponses
tofeverfewextracts.HMOX-1(hemeoxygenase1,alsocalled
HO-1) not only is an essential enzyme in heme catabolism
but also plays a critical role in cell migration. HMOX-1 can
mediate cell migration by regulating the expression of adhe-
sion molecules. De Oliveira and co-workers [40] have shown
that HMOX-1 up-regulated in the microarray analysis.
Cells from the medullar microenvironment and MΦ
appear to establish close contact and to form a functional
relationship with erythrocytes. This is a key feature in
progenitor regulation and diﬀerentiation of all lineages,
including erythroid precursors [41]. Recent work showed
that after HCM treatment such cellular niches could be
seen in vitro cultures. Scanning electron microscopy demon-
strated that MΦ maintained direct contact with the cells,
promoting cellular interaction with the extracellular matrix.
The contact regions were observed by transmission electron
microscopy as adhesion areas between cellular membranes,
and the space between any two cells in an adhesion area con-
tained irregularly distributed extracellular particles, forming
a septate-like zone with electron-dense points, evidencing
the presence of molecules facilitating adhesion between
stromal cells [12, 13].
In 1996, Barb´ e and colleagues [42] showed that the
absence of resident MΦ resulted in immature erythrocyte
release to the bloodstream. It was also observed that MΦ
removal from bone marrow impeded erythroblast adhe-
sion, corroborating the idea that MΦ are important in
erythroblast adhesion and diﬀerentiation. The identiﬁcation
of niches in the present paper shows that HCM may
immunomodulate medullar erythropoiesis caused by MΦ
and stromal cells. The arrangement of cells in niches (islets)
over MΦ may be important for iron turnover, hemoglobin
synthesis, erythropoietin production, and phagocytosis of
expelled erythroblastic nuclei [33].
5. Conclusion
Our results show that in vitro, in vivo and ex vivo treatment
withHCMstimulatedcytokinesimportantincelldiﬀerentia-
tion and survival of speciﬁc monocytic lineage cells and their
precursors. We hope these data will ﬁnd clinical application
as a safe and feasible pharmacological treatment of isolated
mononuclear cells, to enhance therapeutic eﬃcacy.
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